Nothing Special   »   [go: up one dir, main page]

PE20180690A1 - Composiciones de acido obeticolico y metodos de uso - Google Patents

Composiciones de acido obeticolico y metodos de uso

Info

Publication number
PE20180690A1
PE20180690A1 PE2017002334A PE2017002334A PE20180690A1 PE 20180690 A1 PE20180690 A1 PE 20180690A1 PE 2017002334 A PE2017002334 A PE 2017002334A PE 2017002334 A PE2017002334 A PE 2017002334A PE 20180690 A1 PE20180690 A1 PE 20180690A1
Authority
PE
Peru
Prior art keywords
methods
acid compositions
obeticolic acid
refers
obeticolic
Prior art date
Application number
PE2017002334A
Other languages
English (en)
Inventor
Richard G Lancaster
Kay K Olmstead
Masashi Kagihiro
Ikuko Taoka
Mitsuhiro Matono
Mark Pruzanski
David Shapiro
Roya Hooshmand-Rad
Richard Pencek
Lise Eliot
Jeffrey Edwards
Leigh A Macconell
Tonya K Marmon
Cathi Sciacca
Original Assignee
Intercept Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd filed Critical Intercept Pharmaceuticals Inc
Publication of PE20180690A1 publication Critical patent/PE20180690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta referido a formulaciones de acido obeticolico una sal, ester o conjugado de aminoacido farmaceuticamente aceptable del mismo, con estabilidad, disolucion y/ o solubilidad mejoradas, Tambien se refiere a metodos para preparar las mismas, para tratar diversas enfermedades y afecciones como cirrosis biliar primaria (PBC), enfermedad hepatica cronica, entre otros
PE2017002334A 2015-04-27 2016-04-24 Composiciones de acido obeticolico y metodos de uso PE20180690A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
PE20180690A1 true PE20180690A1 (es) 2018-04-23

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002334A PE20180690A1 (es) 2015-04-27 2016-04-24 Composiciones de acido obeticolico y metodos de uso

Country Status (25)

Country Link
US (8) US10052337B2 (es)
EP (3) EP3971199A1 (es)
JP (2) JP6941057B2 (es)
KR (1) KR20170140325A (es)
CN (1) CN107531742A (es)
AU (2) AU2016255045B2 (es)
BR (1) BR112017023161A2 (es)
CA (1) CA2983609C (es)
CL (1) CL2017002727A1 (es)
CO (1) CO2017011535A2 (es)
CR (1) CR20170492A (es)
EA (1) EA201792354A1 (es)
EC (1) ECSP17078433A (es)
IL (2) IL255269B (es)
MA (1) MA41999A (es)
MX (1) MX2017013805A (es)
NI (1) NI201700128A (es)
PE (1) PE20180690A1 (es)
PH (1) PH12017501956A1 (es)
SG (2) SG11201708606VA (es)
SV (1) SV2017005555A (es)
TN (1) TN2017000452A1 (es)
TW (1) TWI723017B (es)
WO (1) WO2016176208A1 (es)
ZA (1) ZA201707981B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
CA3019499A1 (en) 2016-03-31 2017-10-05 Intercept Pharmaceuticals, Inc. Film-coated tablet having high chemical stability of active ingredient
CN109071452A (zh) * 2016-04-13 2018-12-21 英特塞普特医药品公司 治疗癌症的方法
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
WO2018085622A1 (en) * 2016-11-04 2018-05-11 Children's Hospital Medical Center Liver organoid disease models and methods of making and using same
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
JP2020528892A (ja) * 2017-07-24 2020-10-01 インターセプト ファーマシューティカルズ， インコーポレイテッド 同位体標識化胆汁酸誘導体
WO2019106043A1 (en) * 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
AU2019374797A1 (en) * 2018-11-08 2021-05-27 Intercept Pharmaceuticals, Inc. Methods of using obeticholic acid
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
CA3134536A1 (en) * 2019-03-26 2020-10-01 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
WO2020198576A1 (en) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Methods of modulating regulatory t cells
WO2021176430A1 (ru) * 2020-03-06 2021-09-10 Актив Трєнд Лимитєд Применение группы маркеров для диагностики и коррекции лечения первичного билиарного холангита, фармацевтическая композиция и твердая дозированная форма для лечения первичного билиарного холангита
CN111518152B (zh) * 2020-04-23 2022-11-22 江西青峰药业有限公司 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的制备方法及其应用
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
WO2022076683A1 (en) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Methods of treating coronaviral infection with obeticholic acid
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2023181077A1 (en) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Stable liquid composition comprising obeticholic acid or salts thereof
AU2023257308A1 (en) * 2022-04-21 2024-10-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024043842A1 (en) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
WO2024104960A1 (en) 2022-11-15 2024-05-23 Synthon B.V. Stable formulation comprising obeticholic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) * 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
EP1392714B1 (en) 2001-03-12 2005-08-31 Intercept Pharmaceuticals, Inc. Steroids as agonists for fxr
TWI239247B (en) 2001-06-14 2005-09-11 Otsuka Pharma Co Ltd Pharmaceutical composition
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
BR0312426A (pt) * 2002-07-03 2005-12-06 Esperion Therapeutics Inc Composição farmacêutica, métodos para tratar, prevenir ou controlar um colesterol, dislipidemia ou distúrbio relacionado, para reduzir ou evitar um efeito adverso associado com monoterapia de pantetina e para reduzir ou evitar um efeito adverso associado com monoterapia de segundo agente ativo, e, kit
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP2009500163A (ja) * 2005-07-07 2009-01-08 ナノセラピューティクス・インコーポレイテッド 粉末を製粉および調製する方法及びそれにより得られる組成物
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
AU2010224587A1 (en) 2009-03-17 2011-09-22 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
SG175312A1 (en) 2009-04-24 2011-11-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
JP2013525337A (ja) 2010-04-20 2013-06-20 シプラ・リミテッド 医薬組成物
AU2013277429B2 (en) * 2012-06-19 2016-01-14 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
EP3360882B1 (en) 2013-05-14 2020-12-09 Intercept Pharmaceuticals, Inc. 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
EP3043865B1 (en) * 2013-09-11 2020-11-04 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
US20200054650A1 (en) 2020-02-20
US10758549B2 (en) 2020-09-01
CN107531742A (zh) 2018-01-02
US20190076446A1 (en) 2019-03-14
JP2021183651A (ja) 2021-12-02
CO2017011535A2 (es) 2018-01-31
NI201700128A (es) 2018-04-11
US20220133745A1 (en) 2022-05-05
KR20170140325A (ko) 2017-12-20
US10751349B2 (en) 2020-08-25
CA2983609A1 (en) 2016-11-03
US20170035784A1 (en) 2017-02-09
US20200171053A1 (en) 2020-06-04
US20190255071A1 (en) 2019-08-22
EP3971199A1 (en) 2022-03-23
ECSP17078433A (es) 2018-02-28
AU2016255045A1 (en) 2017-11-09
EA201792354A1 (ru) 2018-03-30
TWI723017B (zh) 2021-04-01
SG11201708606VA (en) 2017-11-29
SV2017005555A (es) 2019-01-18
US10052337B2 (en) 2018-08-21
US10646499B2 (en) 2020-05-12
CR20170492A (es) 2018-05-15
TW201703773A (zh) 2017-02-01
US20200046736A1 (en) 2020-02-13
SG10202003110PA (en) 2020-05-28
CL2017002727A1 (es) 2018-04-27
JP2018514534A (ja) 2018-06-07
AU2020205315A1 (en) 2020-08-06
EP3288958A1 (en) 2018-03-07
AU2016255045B2 (en) 2020-04-16
IL255269B (en) 2022-08-01
BR112017023161A2 (pt) 2018-07-24
ZA201707981B (en) 2019-03-27
US20200046735A1 (en) 2020-02-13
EP4371616A3 (en) 2024-08-28
TN2017000452A1 (en) 2019-04-12
EP4371616A2 (en) 2024-05-22
PH12017501956A1 (en) 2018-03-26
MX2017013805A (es) 2018-09-06
MA41999A (fr) 2018-03-07
IL255269A (en) 2018-02-28
IL294575A (en) 2022-09-01
CA2983609C (en) 2024-05-07
WO2016176208A1 (en) 2016-11-03
JP6941057B2 (ja) 2021-09-29
EP3288958A4 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
PE20180690A1 (es) Composiciones de acido obeticolico y metodos de uso
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
MX2019012676A (es) Derivados de 2-aminoquinolina.
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
CO2020001743A2 (es) Métodos de tratamiento para la fibrosis quística
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CO6630139A2 (es) Aptámeros par b-bgf y su uso en el tratamiento de enfermedades y transtornos mediados por b-ngf
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
EA202090860A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CR20160528A (es) Compuestos y composiciones para inducir condrogénesis
AR105319A1 (es) Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
AR100306A1 (es) Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
EA201991595A1 (ru) Активатор nrf2
CL2015002627A1 (es) Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol